Paul Edward Kelly

CIK: 0001658544

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RLMD

RELMADA THERAPEUTICS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

RLMD
RELMADA THERAPEUTICS, INC.
Dec 12, 2025
Award(A)
Stock Appreciation Rights
Direct
828K shares-
RLMD
RELMADA THERAPEUTICS, INC.
Nov 5, 2025
Purchase(P)
Direct
90K shares at avg. $2.20$198K
RLMD
RELMADA THERAPEUTICS, INC.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
400K shares-
RLMD
RELMADA THERAPEUTICS, INC.
May 16, 2025
Purchase(P)
Direct
200K shares at avg. $0.43$86K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 9, 2024
Purchase(P)
Direct
25K shares at avg. $2.59$65K

		Type	Shares	Price		Ownership
Dec 12, 2025	RLMD RELMADA THERAPEUTICS, INC.	Award(A) Stock Appreciation Rights	828,000	-	-	Direct
Nov 5, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	90,000	$2.20	$198,000	Direct
Jun 26, 2025	RLMD RELMADA THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	400,000	-	-	Direct
May 16, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	200,000	$0.43	$86,060	Direct
Sep 9, 2024	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	25,000	$2.59	$64,750	Direct

1-5 of 5 transactions

About Kelly Paul Edward

Kelly Paul Edward (SEC CIK 0001658544) files insider reports with the SEC as Director of RELMADA THERAPEUTICS, INC. (RLMD).

Signal8 holds 5 ownership filings by Kelly Paul Edward, all Form 4s, filed between Sep 11, 2024 and Dec 16, 2025. Those filings report 5 transactions, from Sep 9, 2024 to Dec 12, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Kelly Paul Edward's filings is in CORAL GABLES,, FL.

Recent filings by Kelly Paul Edward

Dec 12, 2025: Grant or award of RLMD derivative securities (Form 4, code A).
Nov 5, 2025: Open-market purchase of RLMD shares (Form 4, code P).
Jun 26, 2025: Grant or award of RLMD derivative securities (Form 4, code A).
May 16, 2025: Open-market purchase of RLMD shares (Form 4, code P).
Sep 9, 2024: Open-market purchase of RLMD shares (Form 4, code P).

Other insiders filing for RELMADA THERAPEUTICS, INC. (RLMD)

Shenouda Maged, Chief Financial Officer
TRAVERSA SERGIO, Chief Executive Officer
Ence Chuck, CA and CO
Fedeli Fabiana, Director
GLASSPOOL JOHN, Director
CASAMENTO CHARLES J, Director

How to read Form 4 transaction codes